title: [Treatment of Chronic Graft versus Host Disease -Review].
abstract: Chronic graft versus host disease (cGVHD) is the major reason of late non-relapse related death after allogeneic hematopoietic stem cell transplantation (allo-HSCT). The therapeutic regimen based on glucocorticoids remains as the standard initial treatment of cGVHD. But due to the significant side effects and unsatisfactory outcomes, particularly for patients with steroid-refractory disease, the more effective and less toxic therapies should be needed. Abnormal regulation for the stable state of T lymphocytes and B lymphocytes for allo-HSCT patients is the current focus of studying cGVHD pathogenesis. This article summarizes the treatment of cGVHD targeted to pathogenic factors and signaling pathways in pathogenetic process.
authors.affiliation: Department of Hematology, Chinese PLA General Hospital,Medical College of Chinese PLA, Beijing 100853, China.
authors.forename: Fei-Yan
authors.initials: FY
authors.lastname: Wang
authors.affiliation: Department of Hematology, Chinese PLA General Hospital,Medical College of Chinese PLA, Beijing 100853, China. E-mail:gaochunji@hotmail.com.
authors.forename: Chun-Ji
authors.initials: CJ
authors.lastname: Gao
mesh_terms: D001402:B-Lymphocytes; D002908:Chronic Disease; D006086:Graft vs Host Disease / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D014184:Transplantation, Homologous